tasimelteon Hetlioz
Selected indexed studies
- Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder. (J Pharm Pract, 2015) [PMID:25092604]
- MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. (Annu Rev Pharmacol Toxicol, 2016) [PMID:26514204]
- Tasimelteon. (, 2006) [PMID:33355733]
_Worker-drafted node — pending editorial review._
Connections
tasimelteon Hetlioz is a side effect of
Sources
- Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery. (2018) pubmed
- Tasimelteon. (2006) pubmed
- Tasimelteon. (2012) pubmed
- Tasimelteon for insomnia. (2011) pubmed
- Tasimelteon: first global approval. (2014) pubmed
- Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder. (2014) pubmed
- MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. (2016) pubmed
- Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder. (2015) pubmed
- Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial. (2025) pubmed
- Circadian Rhythm Sleep-Wake Disorders: a Contemporary Review of Neurobiology, Treatment, and Dysregulation in Neurodegenerative Disease. (2021) pubmed